RSS Parrot

BETA

🦜 @elisaperego78.bsky.social on Bluesky

@bsky.app.profile.elisaperego78.bsky.social@rss-parrot.net

I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline! Brought to you by the RSS Parrot.

---

#LongCovid | researcher | Covid | infectious disease | health, disability, inequality in present and past | human-environment interactions | big data | medicine history | patient-led research | MA PHD| ≠ MD |

Your feed and you don't want it here? Just e-mail the birb.

Site URL: bsky.app/profile/elisaperego78.bsky.social

Feed URL: bsky.app/profile/did:plc:63kyk2vw4c6mn7wdhw6hevo5/rss

Posts: 6

Followers: 1

Published: October 10, 2026 12:37

Key facts #LongCovid is an heterogeneous disease entity. Case definition for LC must acknowledge heterogeneity. When you design clinical trials you can select the best possible sample for the study you plan. But heterogeneity must be acknowledged,…

Published: October 3, 2026 20:05

"There is no cure. I had pain I couldn't treat with standard anti-inflammatory drugs. I had problems walking up the stairs" Skiing star Sofia Goggia on the two viruses which have sidelined her training since last summer, one of which "uncommon in adults" …

Published: October 3, 2026 19:51

We have biomarkers in #LongCovid, including results from scans and tissue biopsies, to name a few. Trials and treatments (where possible) should revolve around these findings, in addition to using symptom-based questionnaires. But many I see revolve around…

Published: September 29, 2026 17:25

#LongCovid is not a neuroimmune disorder. It's a multi-system disease entity with damage well documented in situ across multiple organs and tissues. Neurological and immune manifestations are important, but so is pathology affecting other body systems.…

Published: September 28, 2026 21:42

My new research is out. "Long Covid perspectives" addresses the recognition of #LongCovid as disease entity and patient-led advocacy movement, the paradigm shifts driven by LC advocacy-research, and challenges ahead (Perego 2026, preprint 2023) …